Granulocyte/monocyte apheresis (GMA) selectively removes circulating granulocytes and monocytes; important producers of proinflammatory cytokines. Seven children with new-onset inflammatory bowel disease (IBD) colitis were treated with GMA together with mesalazine, and had significant decreases in Pediatric UC Activity Index (P ¼ 0.018) and Mayo endoscopic score (P ¼ 0.013). We investigated the colonic mucosal cytokine profiles (analyzed with real-time polymerase chain reaction), before and after induction treatment, and in 6 non-IBD controls. Significant decreases were seen in Colony Stimulating Factor 2 (P ¼ 0.018), tumor necrosis factor-a (P ¼ 0.028), interleukin (IL)-23a (P ¼ 0.043), IL-1b (P ¼ 0.028), IL-36g (P ¼ 0.018), IL-10 (P ¼ 0.028), and transforming growth factor beta 1 (P ¼ 0.043) after treatment. In 6 non-IBD controls there were significantly lower levels of IL-12b (P ¼ 0.023) and IL-23a (P ¼ 0.046) compared to the patients with IBD at onset, and IL-22 (P ¼ 0.088) and IL-36g (P ¼ 0.062) showed lower values without reaching significant differences. We speculate that the decreases in colonic mucosal cytokine profiles after treatment may explain the observed clinical efficacy in the GMA-treated children with IBD.
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What Is Known
Granulocyte/monocyte apheresis selectively removes cytokine producing monocytes and granulocytes from the bloodstream. Cytokines manage intercellular communication and trigger and mediate both systemic and local inflammation. The colonic mucosal cytokine profile in children with inflammatory bowel disease colitis is fairly unknown.
What Is New
Significant decreases were seen in mucosal cytokines; CSF-2, tumor necrosis factor-a, interleukin-23a, interleukin-1b, interleukin-36g, interleukin-10, and transforming growth factor beta 1 after induction treatment with granulocyte/monocyte apheresis and mesalazine in children with new-onset inflammatory bowel disease colitis. G ranulocyte and monocyte adsorptive apheresis (GMA) removes activated peripheral blood leukocytes that play a central role in the intestinal inflammation seen in inflammatory bowel disease (IBD) (1, 2) . These immune cells release cytokines that are key signals in the intestinal immune response (3) . Cytokines manage intercellular communication and also trigger and mediate both systemic and local inflammation (4) . GMA may be used as an induction therapy in selected pediatric patients with IBD to achieve disease remission. It is, however, mostly used as last treatment according to the recent pediatric European Crohn's and Colitis Organisation (ECCO)/European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) consensus guidelines (5, 6) . We previously reported the results of GMA together with a low to moderate dose of mesalazine as first line treatment in children with new-onset IBD colitis (7) . In this study we report the colonic mucosal cytokine profiles (CMCP) in children with IBD colitis at new onset and after treatment with GMA together with mesalazine and in non-IBD controls.
CHILDREN AND METHODS
We analyzed CMCP in 7 children with new-onset IBD colitis included in a previous study (7) and in 6 children who underwent endoscopy for suspected gastrointestinal disease, 5 of those were healthy, and 1 patient had a single juvenile polyp. These 6 children are referred to as non-IBD controls. The patients with IBD fulfilled the ECCO/ESPGHAN consensus criteria for pediatric ulcerative colitis (UC) (6) . For technical reasons beyond our control CMCP was only analyzed in 7 of 12 children from the previous study. No active selection was performed.
The patients with UC were planned for treatment with 10 GMA sessions (Adacolumn, JIMRO Co. Ltd, Otsuka Pharmaceuticals Europe Ltd, Wexham, UK) during 5 weeks together with a low to moderate (39-65 mg Á kg À1 Á day À1 ) dose of mesalazine. The inclusion criteria for the GMA treatment were previously healthy children, 12 to 18 years of age, with a body weight !30 kg. The exclusion criteria were any use of immunosuppressive drug within 6 months before diagnosis, UC with limited inflammatory extension according to the Paris classification (E1 or E2) (8) , and a history of perceived anxiety when exposed to intravenous cannulation.
Examinations
All children were investigated according to the ECCO/ESP-GHAN guidelines for pediatric IBD (6) . The clinical activity was evaluated by the PUCAI (Pediatric UC Activity Index) score (9) . All children were investigated with upper endoscopy and ileocolonoscopy under general anesthesia with multiple diagnostic biopsies from 11 sites (ileum to rectum) (5) . Colonic biopsies from the most inflamed sites were analyzed for CMCP. Disease extension (Paris classification) (8) and Mayo endoscopic scoring (10) in the right segment, in transverse colon, in the left segment and in rectum were registered during the procedures. The mucosal biopsies were reviewed by an experienced pathologist using the Geboes scoring system (11) . For the sake of simplicity, we present the proportions (percentage) of biopsies with Geboes score <3 (no IBD inflammation from 11 sites for each child). We aimed to perform a control colonoscopy 12 weeks after the final GMA treatment with similar biopsy harvesting for CMCP and histopathology as the diagnostic endoscopy procedure. The time interval between colonoscopies was chosen based on the suggested time for a steady-state leukocyte transmigration between blood and mucosa (12) . No control colonoscopy was performed in the 6 non-IBD controls.
Adacolumn Treatment
Adacolumn is a 20 Â 9 cm column filled with adsorptive carriers comprising 35,000 cellulose acetate beads. The beads attract the Fc-] receptors of the activated granulocytes and monocytes through antibody complex formations and the key target is thought to be the proinflammatory CD14 þ CD16 þ monocytes, the main producers of the inflammatory cytokine tumor necrosis factor (TNF) in human blood (2, 13) . The granulocyte adsorption ability of Adacolumn is more than 2.18 Â 10 9 cells (approximately 65% of granulocytes, 55% of monocytes, and 2% of leukocytes) when the blood is circulated through the column at a flow rate of 30 mL/min for a duration of 60 min (14) (15) (16) . During apheresis, the blood is perfused from the cubital vein of 1 arm, perfused through the column and returns to the cubital vein in the contralateral arm.
Cytokine Selection
A panel of cytokines known to participate in chronic intestinal inflammation was selected for testing. We investigated CSF-2, interferon g (IFN-g), TNF-a, interleukin 1b (IL-1b), IL-4, IL-5, IL-6, IL-10, IL-12B, IL-13, IL-22, IL-23a, IL-36g, TGF-b1, and a control gene ABL CT. The amount of mRNA in the 14 different proinflammatory mediators was compared to the signal from the ABL gene and the result is presented as the ratio cytokine/ABL. We used TaqMan Gene Expression Assays, Applied Biosystems (Thermo Fischer Scientific, Waltham, MA).
RNA Extraction and Gene Expression by Real-time Polymerase Chain Reaction
Biopsies for CMCP were put into RNA-later (Invitrogen, Waltham, MA) and kept at þ68C for 24 hours and then frozen (À208C) until analysis.Total RNAwasisolated utilizingtheFibrous tissue kit (Qiagen, Hilden, Germany) with slight modification. Defrosted and minced biopsies (3 mm) were homogenized with a pestle motor (WVR, Radnor, PA) for 30 to 60 seconds in 350 mL RLT buffer and 350 mL 70% ethanol was added. The homogenates were loaded to spin columns, centrifuged, and the columns were washed with 350 mL RW1 buffer. Samples in columns were treated by DNase I and washed with 350 mL RW1 buffer, the remainder handled according to the manufacturer protocol. cDNA was obtained by reverse transcription. Quantitative real-time polymerase chain reaction (qPCR) was performed using the 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA) for quantification. Probes were obtained from Applied Biosystems, TaqMan MGB probes, FAM dye-labeled; IL1 (Hs00174097_m1), IL-4 (Hs00174122_m1), IL5 (Hs01548712_g1), IL6 (Hs00985639_m1), IL10 (Hs00961622_ m1), IL12 (Hs001011518_m1), IL13 (Hs00174379_m1), IL22 (Hs01574154_m1), IL23 (Hs00900828_g1), IL36 (Hs00219742_ m1), TGFbeta (Hs00998133_m1), TNFa (Hs01113624_g1), IFN-g (Hs00989291_m1), GM-CSF (Hs00929873_m1), ABL1 (Hs01104728 _m1) according to manufacturer protocol. Fold increases of mRNA transcripts were calculated as follows: DCt ¼ Ct (gene of interest) À Ct (ABL1), DDCt ¼ DCt sampleÀaverage DCt control group, and fold difference ¼ 2ÀDDCt.
Ethical Approval
The study was approved by the local Ethics Committee in Stockholm, Sweden (no. 2011/1927-31/2). Informed written consent was obtained from legal guardians and also from all children older than 15 years before any study-related procedure was initiated, in accordance with the Helsinki II Declaration.
Statistics
Comparisons between clinical chemistry test, Mayo endoscopic score and PUCAI before and after treatment, were conducted with paired sample t tests (parametric data) or Wilcoxon paired t test (nonparametric data) depending on the normal distribution (tested with Shapiro-Wilks test). Comparisons between cytokines (tested for normal distribution and found to be nonparametric) before and after treatment were conducted with Wilcoxon paired t test (paired data) and Mann-Whitney U test for test between patients with IBD and non-IBD controls (unpaired data). All analyses were performed with the IBM SPSS Statistics Data Editor, version 23. Statistical significance was set at P < 0.05.
RESULTS

Children and Clinical Outcome
Seven children, 5 boys, mean age 14.3 years (range 12.3-15.9) were initially diagnosed as UC according to the ECCO/ ESPGHAN diagnostic criteria (5) . After completion of the study, a histopathological review was performed and in 2 patients the diagnosis was changed to Crohn colitis (Table 1 ).
All 7 patients with IBD completed the 10 planned GMA sessions. The median time to completion of the GMA sessions was 6 weeks (range 4.5-8). The control colonoscopy was performed at median 13 weeks (range 9-17) after the last GMA session.
Clinical Outcome and Colonic Mucosal Cytokine Profiles in 7 Children at Inflammatory Bowel Disease Onset and After Induction Treatment
Clinical and Endoscopic Remission
At inclusion the median PUCAI was 50 (interquartile range [IQR] 40-70, range 30-80). At time for control colonoscopy there was a significant improvement in PUCAI (median 0, IQR 0-15, range 0-25) (P ¼ 0.001) ( Table 1) .
The endoscopic Mayo scoring showed a significant improvement (P ¼ 0.013) between inclusion (median 7, IQR 6-9, range 6-12) and control colonoscopy (median 3, IQR 0-3, range 0-6) ( Table 1) . At onset, the histological Geboes score <3 (no inflammation) was found in none of the biopsies from 4 patients, and in 10% to 30% of the biopsies from 3 patients. At control colonoscopy Geboes score <3 was seen in none of the biopsies in 1 patient, in 25% to 40% of the biopsies from 3 patients, in 70% to 75% of the biopsies from 2 patients, and in all biopsies from 1 patient.
One child was treated with prednisolone (1.5 mg Á kg À1 Á day À1 ) due to a flare between completion of the 10 GMA sessions and control colonoscopy. At the time of control endoscopy this child had mild disease but no endoscopic or histologic remission.
Long-term Follow-up
Seven patients were monitored for more than 1 year (range 34-48 months after inclusion), 5 of 7 continued with mesalazine and did not require immunosuppressive or corticosteroid treatment. Two of 7 received 1 prednisolone treatment each due to flares, 1 during the time between GMA and the control endoscopy and 1 several months after the control endoscopy.
Colonic Mucosal Cytokine Profiles
Significant decreases were seen in CSF-2 (P ¼ 0.018), TNFa (P ¼ 0.028), IL-23a (P ¼ 0.043), IL-1b (P ¼ 0.028), IL-36g (P ¼ 0.018), IL-10 (P ¼ 0.028), and TGF-b1 (P ¼ 0.043) in the intestinal mucosa after induction treatment. IL-4 (P ¼ 0.068), IL-5 (P ¼ 0.068), and IL-6 (P ¼ 0.075) showed a decreasing trend without statistical significance. No significant differences were seen in IFN-g (P ¼ 0.176), IL-12b (P ¼ 0.499), IL-22 (P ¼ 0.398), and IL-13 (P ¼ 0.138) (Fig. 1) .
Cytokine Comparison Between Inflammatory Bowel Disease Colitis Patients and Noninflammatory Bowel Disease Controls
In 6 non-IBD controls, CMCP showed significantly lower IL-12b (P ¼ 0.023) and IL-23a (P ¼ 0.046) compared to the 7 patients with IBD. Lower expression of IL-22 (P ¼ 0.088), and IL-36g (P ¼ 0.62) was also shown in the non-IBD patients without reaching statistical significance.
Colonic Mucosal Cytokine Profiles in 2 Children With Crohn's Disease
Post-treatment cytokine expression in the 2 CD colitis patients after induction treatment was overall decreased except for an increase in IL-12b in 1 patient.
Colonic Mucosal Cytokine Profiles in 1 Child Treated With Prednisolone
The child did not achieve remission, yet CSF-2, IFN-g, TNFa, IL-12b, IL-23-a, IL-36g, TGF-b1, and IL-1b decreased and IL-22 increased after induction treatment. Il-4, IL-5, IL-6, IL-10, and IL-13 were not measured due to technical difficulties.
DISCUSSION
In the present study, we investigated the CMCP by real time PCR to study the effects of GMA together with a low to moderate dose of mesalazine in children with new-onset IBD colitis. We also compared CMCP from the diagnostic endoscopy between the IBD patients and non-IBD controls. We found clinical and endoscopic improvements as well as significant decreases in mucosal cytokines at control colonoscopy. Fourteen different cytokines were investigated and significant decreases were seen in CSF-2, TNF-a, IL-23a, IL-1b, IL-36g, IL-10, and TGF-b1 and non-significant decreases in IL-4, IL-5 and IL-6. We also found significantly higher IL-12b and IL-23a and higher expression of IL-22 and IL-36g between the IBD patients and the non-IBD controls. In one child, who was treated with prednisolone between the tenth GMA and control colonoscopy and who was not in remission, the CMCP showed a decrease in most cytokines. Yamamoto et al (17) studied the clinical and endoscopic remission and mucosal cytokine profiles after GMA in 28 UC adult patients with moderately active disease. Our findings corroborate their results that showed significant decreases in IL1b, IL-6, and TNF-a, but also in IL-8 and a significantly increased IL-1ra/IL-1b ratio. Velikova et al (18) studied alterations in cytokine gene expression profile in colonic mucosa in 37 adult patients with IBD and 12 non-IBD patients. They found upregulated genes for cytokines in the following order: IL-6 > FoxP3 > TGF-b1 > IL-23 > IL-17A > IL-10, in the inflamed mucosa of the patients with IBD and significantly higher gene expression of FoxP3, TGF-b1, and IL-6 in the patients with IBD compared to the non-IBD patients. By correlating cytokine gene expression in patients with IBD treated with different therapeutic regimens they found that immunosuppressive therapy was more beneficial than 5-aminisalicylic acid to restore immune regulation in patients with IBD. Linton et al (19) showed increased levels of CD14(þ)HLA-DR(hi) circulating monocytes, that produce high levels of inflammatory mediators in patients with active IBD compared to healthy controls. After treatment with GMA and corticosteroids the proportion of circulating CD14(þ)HLA-DR(hi) monocytes were significantly reduced which may explain the reduction in mucosal cytokine expression. Tanaka et al (20) showed that responders to GMA had restoration of mucosal erosions and ulcers and a marked reduction of infiltrating leukocytes, and further that steroid naïve patients with short duration of UC were the best responders. Their findings are in line with our findings of significantly decreased endoscopic Mayo score, and improved histological scoring, with a decrease of the neutrophil infiltration in the epithelium in a majority of our study group.
To the best of our knowledge, our study is the first to analyze CMCP in children after induction of remission with GMA and mesalazine in new-onset IBD colitis. The weakness of this study is the low number of patients included. Studies of cytokine profiles in colonic mucosa after GMA is an unexplored field with only a few other small studies available. Our findings are in line with previous results from studies in adults and show that GMA decreases the expression of TNF-a, a known key-cytokine in the pathogenesis of IBD, and several other inflammatory cytokines, that perpetuate the intestinal inflammation in a vicious circle. We speculate that the findings of decreased cytokine expression may explain the observed clinical efficacy in the GMA and mesalazine-treated children. TNF-α at diagnosis and control endoscopy 
